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In-vivo generation of bone via endochondral
ossification by in-vitro chondrogenic priming of
adult human and rat mesenchymal stem cells
Eric Farrell1,2*†, Sanne K Both3†, Kathrin I Odörfer4, Wendy Koevoet2, Nicole Kops1, Fergal J O’Brien5,6,
Robert J Baatenburg de Jong2, Jan A Verhaar1, Vincent Cuijpers3, John Jansen3, Reinhold G Erben4,
Gerjo JVM van Osch1,2
Abstract
Background: Bone grafts are required to repair large bone defects after tumour resection or large trauma. The
availability of patients’ own bone tissue that can be used for these procedures is limited. Thus far bone tissue
engineering has not lead to an implant which could be used as alternative in bone replacement surgery. This is
mainly due to problems of vascularisation of the implanted tissues leading to core necrosis and implant failure.
Recently it was discovered that embryonic stem cells can form bone via the endochondral pathway, thereby
turning in-vitro created cartilage into bone in-vivo. In this study we investigated the potential of human adult
mesenchymal stem cells to form bone via the endochondral pathway.
Methods: MSCs were cultured for 28 days in chondrogenic, osteogenic or control medium prior to implantation.
To further optimise this process we induced mineralisation in the chondrogenic constructs before implantation by
changing to osteogenic medium during the last 7 days of culture.
Results: After 8 weeks of subcutaneous implantation in mice, bone and bone marrow formation was observed in 8 of
9 constructs cultured in chondrogenic medium. No bone was observed in any samples cultured in osteogenic medium.
Switch to osteogenic medium for 7 days prevented formation of bone in-vivo. Addition of b-glycerophosphate to
chondrogenic medium during the last 7 days in culture induced mineralisation of the matrix and still enabled
formation of bone and marrow in both human and rat MSC cultures. To determine whether bone was formed by the
host or by the implanted tissue we used an immunocompetent transgenic rat model. Thereby we found that
osteoblasts in the bone were almost entirely of host origin but the osteocytes are of both host and donor origin.
Conclusions: The preliminary data presented in this manuscript demonstrates that chondrogenic priming of MSCs
leads to bone formation in vivo using both human and rat cells. Furthermore, addition of b-glycerophosphate to
the chondrogenic medium did not hamper this process. Using transgenic animals we also demonstrated that both
host and donor cells played a role in bone formation. In conclusion these data indicate that in-vitro chondrogenic
differentiation of human MSCs could lead to an alternative and superior approach for bone tissue engineering.
Introduction
Bone can be damaged by trauma or disease and often
bone graft substitutes are then needed for repair. Substi-
tute bone can be derived from the patient (autograft) or
from a donor (allograft). The common treatment is to
use autologous bone grafts but this method has its draw-
backs. It causes the generation of a second surgical site
with increased donor site morbidity. Secondly, availability
of autologous bone is limited [1]. With the other option,
using allograft material, there are risks of immune reac-
tion and disease transmission [2]. For this reason, there is
a huge interest in developing new strategies for bone
replacement. Marrow derived progenitor cells of adults
represent a promising source of therapeutic tool and are
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known to differentiate along various mesenchymal
lineages. The use of adult bone marrow stromal cells
(MSCs) to achieve bone and cartilage formation and
repair have met with less success and more problems
than expected [1]. In relation to bone formation, one of
the largest problems has been nutrient delivery and waste
removal associated with a lack of vasculature in
implanted tissues leading to core necrosis and implant
failure. It is clear that vascularisation is a critical consid-
eration for any regenerative medicine approach [3,4].
Cartilage is an avascular tissue and, hence, does not suf-
fer from this problem. However, regenerative medicine
approaches to cartilage regeneration have also met with
problems [5], mainly because of the tendency of MSCs to
naturally progress from forming stable, collagen type II
expressing, cartilage to a more hypertophic phenotype
characterised by expression of collagen type X.
In a recent paper we hypothesised that the natural
tendency of chondrogenically primed MSCs to become
hypertrophic might be a very desirable trait for bone tis-
sue engineering applications [6]. MSCs have been
shown to progress along similar stages of endochondral
ossification as observed during development [7]. Recent
successes in the induction of endochondral ossification
from embryonic stem cells and murine bone marrow
cells supported the feasibility of such an approach
[8-10]. There are several rationales behind the hypoth-
esis that this route of bone formation would be more
successful than intramembranous ossification. Firstly,
chondrocytes normally reside in an avascular tissue and
as a result are “designed” to function in a low oxygen
environment, similar to what they would encounter
upon implantation into an unvascularised region [11].
Secondly, as stated, MSCs under in-vitro conditions
(almost) always become hypertrophic when cultured
chondrogenically, the next step in the endochondral
ossification pathway [7,12]. Thirdly, the release of fac-
tors from primed chondrogenic cells progressing along
the endochondral route would be much more complex
and controlled spatiotemporally than any growth factor
combination we could devise in order to improve
in-vivo vascularisation and bone formation. Previously
[6], we demonstrated that chondrogenically primed
MSC seeded scaffolds did indeed survive 4 weeks
in-vivo without core necrosis as evaluated histologically.
Furthermore, we observed blood vessels in the chondro-
genic samples only and data suggested that this was due
to release of VEGF from these constructs as measured
in-vitro in chondrogenic pellets. However, we did not
observe bone formation in any of the samples in-vivo
after 4 weeks. We hypothesised that either samples
were not primed for long enough in-vitro or they were
not maintained in-vivo for long enough to allow the
process to occur.
In the current experiment we cultured MSC seeded
scaffolds for a longer period in-vitro to allow cells to
migrate into the scaffolds prior to priming and to poten-
tially form more matrix prior to implantation. In addi-
tion, samples were maintained in-vivo for a minimum of
8 weeks. Our aim was to answer 3 specific questions.
Firstly can adult human MSC seeded scaffolds undergo
endochondral ossification in-vivo to form bone for the
purposes of bone repair/replacement? Secondly, can this
process be further optimised by allowing mineralisation
to occur in-vitro for a brief period of time before
implantation, thereby speeding up or enhancing the
quantity of bone formed. Thirdly, what is the role of the
donor and host cells in the process of endochondral
ossification? To answer this final question we used a
transgenic rat model ubiquitously expressing human
placental alkaline phosphatase (hPLAP) as a recipient of
wild type cells [13,14].
Materials and methods
human bone marrow cell culture
Bone marrow aspirates were obtained from three
donors, 47, 57 and 69 years of age undergoing total hip
arthroplasty after informed consent with approval of the
local medical ethical committee (METC2004-142). The
aspirates were plated as previously described [6].
To create a pellet, suspensions of 200,000 cells per
15 ml tube were centrifuged at 200 g for 8 minutes. For
the scaffolds, suspensions of detached cells were seeded
with 1*106 cells per scaffold, divided into 500,000 cells
in 100 μl on each side of the Collagen-GAG scaffolds as
described previously [15]. The constructs were cultured
for 7 days in medium as used for expansion (control
medium). Afterwards all samples were either maintained
in control medium or replaced with chondrogenic or
osteogenic medium for 28 days. Half of the medium was
replaced every 3 days.
Chondrogenic medium consisted of high-glucose
DMEM containing 50 mg/mL of gentamicin and 1.5 mg/
mL of Fungizone (Invitrogen) 25 μg/ml L-ascorbic acid
2-phosphate, 100 mM of sodium pyruvate (Invitrogen),
1:100 insulin-transferrin-selenium (ITS; BD Biosciences,
Bedford, MA), 10 ng/mL of transforming growth factor
beta-2 (TGF-b2), (R&D Systems, Abingdon, United King-
dom) and 100 nM dexamethasone (Sigma, St. Louis,
MO). The osteogenic medium consisted DMEM contain-
ing 10% fetal calf serum (Gibco, selected batch), gentami-
cin and 1.5 mg/mL of Fungizone (Invitrogen) 0.1 mM L-
ascorbic acid 2-phosphate, 10 mM beta-glycerol phos-
phate, 100 nM dexamethasone.
To investigate if bone formation in vivo can be
enhanced by allowing mineralisation to occur before
implantation, we have applied chondrogenic medium for
21 days and then switched to mineralizing medium
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conditions for the last 7 days of culture. For the switch 1
condition the chondrogenic medium was replaced after
21 days of culture with osteogenic medium for the
remaining period of 7 days. For the switch 2 condition
after 21 days of culture in chondrogenic medium, 10 mM
beta-glycerol phosphate (as a source of phosphate to
allow for mineralization) was added to the chondrogenic
medium for the remaining period of 7 days.
Gene expression analysis
To confirm chondrogenic potential of MSCs prior to
implantation, gene expression analysis of GAPDH, Sox9,
cbfa1, collagen type II and collagen type X was per-
formed as described previously [16] In addition, samples
cultured as pellets were harvested from each MSC
donor, fixed in 4% phosphate buffered formalin and
embedded in paraffin for collagen type II immunohisto-
chemistry (II-II6B3 antibody, 1:100; Developmental Stu-
dies Hybridoma Bank, Iowa City, IA, under contract
N01-HD-6-2915 from the National Institute of Child
Health and Human Development).
In vivo implantation of hMSC
To evaluate bone formation, cultured constructs were
implanted subcutaneously in athymic mice (Balb/C
nudes, CDL Nijmegen). For each donor, 3 constructs of
each condition were implanted. Before surgery, the skin
on both lateral sites of the spine was cleaned with 70%
alcohol and 4 subcutaneous pockets were created in
each mouse. The tissue engineered samples or pellets
were inserted and the pockets closed. Three empty scaf-
folds were also implanted. Two of these were main-
tained for the duration of the culture period in
expansion medium and one of these in chondrogenic
medium. Eight and fourteen weeks after surgery, the
animals were euthanized by CO2. The explanted samples
were fixed in 4% paraformaldehyde, decalcified in formic
acid and embedded in paraffin. The experiments were
approved by the Dutch animal experiment committee.
Micro CT imaging
All samples were scanned using micro-CT (Skyscan
model 1072, Kontich, Belgium) with a source of 50 kV/
98mA without using a filter (resolution 8.1 μm per
pixel). Each sample was rotated 180 degrees with a rota-
tion step of 0.90 degrees, exposure time 2.9 seconds. 3D
reconstruction, analysis and visualizations were made
with NRecon version 1.6, CT-analyzer V1.9 (Skyscan)
and 3D-Doctor™ (Able Software Corp., Lexington,
United States).
Histomorphometrical analysis
Sections were stained with haematoxylin-eosin and eval-
uated for presence or absence of bone. A Fisher exact
test was used to evaluate statistical significance. Histo-
morphometry was performed on 2-4 sections of each
sample. From each section, low magnification digital
images were made, images were pseudo colored and
measurements were performed with image analyses
techniques (Leica Qwin Pro-image analysis system,
Wetzlar, Germany) to obtain the percentage of bone,
bone marrow and other tissue.
Rat MSC isolation, culture and implantation
MSCs from 5 month-old inbred wild-type Fischer 344
(F344) rats were isolated and cultured according to stan-
dard procedures as described elsewhere [15]. Culture
and scaffold seeding was performed exactly as for the
human MSCs as described above. The second switch
condition was employed for the rat component of this
study. Following 5 weeks in vitro, three constructs (scaf-
folds) of each condition were implanted subcutaneously
into immunocompetent co-isogenic hPLAP-transgenic
(human Placental Alkaline Phosphatase) F344 rats for 8
weeks. Animals were sacrificed by exsanguination under
ketamine/xylazine anesthesia. Scaffolds were harvested
and fixed in 40% ethanol at 4°C for 48 h, dehydrated
and embedded in modified methylmetacrylate [17].
Immunohistochemistry for collagen type II
To analyze collagen type II expression, sections were
incubated with 0.1% pronase (Sigma, St Louis, MO) for
antigen retrieval and 1% hyaluronidase (Sigma, St Louis,
MO). Sections were incubated for 2 h at room tempera-
ture with mouse monoclonal antibody against collagen
type II (II-II6B3 antibody, 1:100; Developmental Studies
Hybridoma Bank, Iowa City, IA, under contract N01-
HD-6-2915 from the NICHD).
hPLAP immunohistochemical staining
For histochemical staining of the marker enzyme hPLAP
deplastisized sections were rehydrated and heated at
65°C for 30 min in deionized water to block endogenous
alkaline phosphatase activity. Cells expressing hPLAP
were histochemically stained by incubation with an AP
substrate (TRIS-HCl buffer (0.2 M, pH 8.5) containing
Naphtol AS-MX 0.3 mg/ml (Sigma) and New Fuchsin
0.1 mg/ml (Chroma)) at room temperature for 1 hour
and counterstained with haematoxylin.
Results
Bone formation occurs following chondrogenic priming
of MSCs
In order to confirm chondrogenic differentiation of
MSCs prior to implantation, chondrogenically primed
samples were analysed by realtime qRT-PCR for com-
mon chondrogenic and hypertrophic markers and com-
pared to monolayer controls. Expression of sox 9,
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collagen type II, cbfa1 and collagen type X were signifi-
cantly elevated compared to monolayer control levels
(Control values set to 1 for each gene, Figure 1Ai).
Immunohistochemistry for collagen type II performed
on pellets cultures also confirmed the chondrogenic
potential of MSCs from all donors (Figure 1Aii).
Upon culture of MSCs in scaffolds under chondro-
genic conditions and subsequent implantation, bone for-
mation was observed in 5 out of 6 scaffolds (Figure 1C
iii,) from two different MSC donors. In a third donor
bone formation did not occur in scaffolds however was
observed in chondrogenically primed pellets, which will
be discussed further. Bone formation occurred mainly at
the edges of scaffolds and appeared to be progressing
inwards by the presence of calcified cartilage interior to
the bone and marrow regions. This structural organisa-
tion of the bone regions was confirmed by μCT (Figure
1B). Histomorphometry revealed that 11 ± 5% of the
construct area was bone tissue, 5% was bone marrow
and the rest was qualified as other tissue, consisting of
remnants of scaffold material, cartilaginous tissue and
fibrous tissue. The newly formed bone tissue was lined
with cells resembling osteoblasts and was associated
with bone marrow replete with red blood cells, stroma
and fat cells. In no other treatment condition was bone
or marrow tissue observed. In the scaffolds cultured in
control medium (Figure 1C, n = 6, from 2 donors), or
osteogenic medium (Figure 1C, n = 6 from 2 donors) or
in scaffolds switched to osteogenic medium for 1 week
(Figure 1C, n = 6 from 2 donors), mineralised tissue was
observed both histologically and by μCT (Figure 1B), but
this lacked any significant structural organisation or sur-
rounding marrow. This mineralisation was also observed
to a lesser degree within empty scaffolds after 8 weeks
in vivo.
Osteogenic culture or switch prevents endochondral
ossification but addition of b-glycerophosphate does not
Following the results observed in donors 1 and 2, the
osteogenic condition was discontinued with donor 3. In
addition to the complete switch to serum containing
osteogenic medium for the last culture week, samples
were maintained on chondrogenic medium with b-glycer-
ophosphate to achieve mineralisation of the matrix as
observed previously [6]. This experiment was performed
with cell-seeded scaffolds and pellet cultures. Bone forma-
tion was observed in all pellets that were primed chondro-
genically (Figure 2Ai) confirming results of the
experiments with scaffolds. Once again, under the initial
switch conditions of culturing cells for 1 week in osteo-
genic medium after 3 weeks in chondrogenic medium, no
endochondral ossification or bone formation was observed
(Figure 2Bi). Only one of the three implanted pellets of the
second switch condition where b-glycerophosphate was
added to the chondrogenic medium, was retrieved. Inter-
estingly, in this condition bone formation was observed
to occur similarly to the chondrogenic condition (Figure
2Ci). Once again, a marrow stroma was also observed
within the pellets around the area of bone formation. This
effect was also observed in all 3 scaffold samples that were
cultured under identical conditions in the rat study. Addi-
tion of b-glycerophosphate did not prevent bone forma-
tion in vivo. Histomorphometry (Figure 2Aii, Bii, Cii)
revealed that in the pellet constructs with bone formation
32 ± 10% of the construct area consisted of bone tissue,
and 37 ± 24% of bone marrow. The rest of the area (39 ±
27%) was cartilage as confirmed by positive collagen type
II immunohistochemistry. This data is presented in Table
1. Safranin O staining of these pellets showed the presence
of small amounts of GAGs remaining in the cartilage like
matrix. This indicates that in this phase most proteogly-
cans have been degraded, a process which occurs during
endochondral ossification. Figures 2E and 2F demonstrate
all stages of endochondral ossification in the same pellet,
cartilage degradation, blood vessel invasion and bone and
marrow formation.
We also retrieved a chondrogenically primed pellet
implanted in-vivo for 14 weeks. This construct had 24%
± 7 bone tissue and 76% ± 7 marrow. No other tissue
was present. Bone tissue was located at the outer rim of
the construct (Figure 2Di and 2ii). As stated above no
bone formation was observed in the scaffolds from
donor 3. However, this was due to poor cell seeding of
the scaffolds as identified by a very low cell number in
scaffolds prior to implantation as identified by histologi-
cal assessment of un-implanted samples.
Role of host and donor cells
In order to determine the role of host and donor cells in
the generation of tissue engineered bone via endochon-
dral ossification the described experiments were
repeated in an immunocompetent model using hPLAP
transgenic rats. This model enabled specific staining of
alkaline phosphatase activity to distinguish host and
donor cells from one another to determine the origin of
the various cells observed in the constructs upon retrie-
val. Similar to the implanted human cells, bone forma-
tion occurred in all chondrogenically primed samples
(Figure 3A&3B). Once again no bone formation
was observed in any of the constructs that were cultured
in osteogenic medium (data not shown). As was
observed in the switch 2 condition, maintained in chon-
drogenic medium for 3 weeks and simply supplied with
b-glycerophosphate during the last week, bone forma-
tion was observed in two of the three constructs (data
not shown). Most important in this experiment was the
question of whether the bone that was formed was host
or donor derived. Staining for the human placental
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Figure 1 Chondrogenic priming of MSCs seeded into Collagen GAG scaffolds in-vitro leads to bone formation in-vivo. Figure 1A;
Chondrogenic potential was confirmed in all three donors by PCR (donors 1 and 2, expression relative to undifferentiated donor matched
controls) and collagen type II immunohistochemistry (Figure 1Aii Donors 1-3). Figure 1Aiii, Toluidine Blue staining of a chondrogenically primed
scaffold prior to implantation. Figure 1B Micro computed tomography of retrieved constructs (resolution 8.1 μm per pixel). The pattern of bone
formation observed histologically matched closely with these images showing bone tissue at the edges of the constructs. Mineralised matrix
that did not form bone was also observed in all constructs as well as empty scaffold controls. Figure 1C; Hameatoxylin and Eosin staining of
bone formation in chondrogenically primed constructs (1Ciii) as compared to constructs cultured in osteogenic (Figure 1Cii) medium for 4
weeks. While osteogenically primed samples were more mineralised compared to in-vitro samples, no true bone formation was observed. Switch
from chondrogenic to osteogenic medium for 7 days also prevented in-vivo bone formation (Figure 1Civ). Insets represent lower magnification
images of the constructs. Arrow indicate blood vessels in each construct.
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Figure 2 Osteogenic culture or switch prevents endochondral ossification but addition of b-glycerophosphate does not. Representative
hematoxilin-eosin stained slides of implanted pellets in immune deficient mice for 8 weeks. Primed chondrogenically bone, cartilage and
marrow stroma are visible (Ai). For the switch 1 condition the chondrogenic medium was replaced during the last 7 days for osteogenic
medium which resulted in cartilage-like tissue in the inside and undefined tissue on the outside (Bi). For the switch 2 condition b-
glycerophosphate was added during the last 7 days of culture and bone, cartilage and marrow stroma are observed (Ci). When the
chondrogenic primed pellets were implanted for 14 weeks only bone and marrow stroma were visible. For quantitative analysis all pictures were
pseudo colored, red (bone), blue (marrow stroma) green (cartilage), undefined tissue (yellow) (Aii, Bii, Cii, Dii). Figure 2, E and F show Safranin O
staining of in vitro chondrogenically cultured pellets retrieved after 8 week in vivo. Weakly positive staining demonstrates the presence of
glycosaminoglycans within a cartilage matrix being degraded to make way for bone and marrow formation which surrounds the remnants of
the cartilage matrix.
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alkaline phosphatase activity found only in host cells
demonstrated that the osteoblasts were almost entirely
of host origin. Interestingly, there was a mixed popula-
tion of osteocytes embedded in the bone that stained
both positively and negatively(Figure 3C), suggesting
that donor-derived cells do indeed participate in bone
formation at earlier stages after implantation.
Discussion
Tissue engineering approaches to bone repair have thus
far been disappointing. Recent interest has focused on
the process of endochondral ossification as a possible
means to generate bone for regenerative medicine pur-
poses [6,8,18-20]. The release profile of factors that
occurs during endochondral ossification is complex and
coordinates the formation of bone from a cartilage
template [21]. Here we show that chondrogenically dif-
ferentiated adult human and rat MSCs seeded into col-
lagen GAG scaffolds give rise to bone formation via
endochondral ossification in-vivo. Previously, it was
demonstrated that this was possible with murine
embryonic stem cells [8] as well as murine adult bone
marrow stromal cells [9,10]. The data from our study
are also supported by the recent publication by Chan et
al [22] demonstrating that endochondral ossification is
required for haematopoietic stem cell niche formation
with a subpopulation of foetal progenitor cells giving
rise to bone with a marrow cavity only if they would
normally undergo endochondral ossification as opposed
to intramembranous ossification. Even more recently,
Janicki et al [23] demonstrated the same mechanism of
bone formation via endochondral ossification using
Table 1 Description of treatment conditions and semi-quantitative measurement of bone and marrow formation in
scaffold constructs and pellets
Donor Treatment Implanted Bone formed % Bone % Marrow
1 Control in scaffold 3 0/3 0 0
Osteogenic in scaffold 3 0/3 0 0
Chondrogenic in scaffold 3 3/3 9 ± 3 8 ± 7
Switch 1 (switch to osteogenic culture) in scaffold 3 0/3 0 0
2 Control in scaffold 3 0/3 0 0
Osteogenic in scaffold 3 0/3 0 0
Chondrogenic in scaffold 3 2/3 13 ± 7 6 ± 7
Switch 1 (switch to osteogenic culture) in scaffold 3 0/3 0 0
3 Chondrogenic in scaffold 3*
Switch 1 (switch to osteogenic culture) in scaffold 3*
Switch 2 (+b-glycerophosphate) in scaffold 3*
3 Chondrogenic in pellet 3 3/3 32 ± 10 37 ± 24
Switch 1 (switch to osteogenic culture) in pellet 3 0/2 0 0
Switch 2 (+b-glycerophosphate) in pellet 3 1/1 23 52
14 weeks chondrogenic in pellet 3 2/2 24 ± 7 76 ± 7
Results are average ± SD. *Donor 3 scaffolds were not analysed because of poor cell seeding as determined in pre-implantation samples by histology and RNA
content.
Figure 3 Role of host and donor cells. By implanting in transgenic rats we can distinguish between donor and host with a hPLAP
immunohistochemical staining. Overview of the implanted scaffold in which bone and bone marrow can be observed on hematoxilin-eosin A)
and von Kossa (B) staining. All osteoblasts are stained red indicating they are from the host (C). The osteocytes however embedded in the bone
are of both host (arrowheads) and donor origin (arrows).
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human MSCs and b-tricalcium phosphate with a 6 week
in-vitro chondrogenic pre-culture.
Initial results presented in this manuscript demon-
strate that eight weeks of implantation was not sufficient
to ossify the complete construct. In case of a completely
cartilaginous construct (such as the pellets we used) the
remaining tissue is cartilage and the sample harvested
after 14 weeks demonstrated that the complete con-
struct is subsequently turned into bone and bone mar-
row. The bone is then only localised at the outer rim,
probably due to a lack of mechanical stimulation that is
prerequisite for bone maintenance. The technical pro-
blems associated with homogenous cell seeding will
likely become relevant when upscaling the procedure
towards application in patients. Use of bioreactors to
improve cell seeding efficiency and also mechanical
integrity could be considered [24-26].
Addition of b-glycerophosphate
An important consideration in the generation of bone
via endochondral ossification is the optimum differentia-
tion stage at which one can implant. Ideally, the further
along the differentiation pathway a construct is prior to
implantation the faster it would fulfil its role in-vivo. To
assess this we cultured scaffolds in both osteogenic
medium as a negative control of bone formation and in
chondrogenic medium for 3 weeks with a switch to
standard osteogenic medium for one week (switch 1) to
begin the osteogenic differentiation process. Despite the
brief period of exposure to these culture conditions, no
bone formation was observed in-vivo. We hypothesised
this was due to a lack of vascularisation due to reduced
release of pro-angiogenic factors that we had previously
observed in-vitro [6]. However upon close inspection,
blood vessels were observed in all 4 culture conditions.
As a further evaluation of the effect of the presence of
mineralisation before implantation, we simply added b-
glycerophosphate to the chondrogenic media for 1 week
which we had also shown previously to cause minerali-
sation. Unfortunately only a single pellet was retrieved
in the human MSC pellets as the other two could not
be located. However, bone formation under this switch
2 (glycerophosphate only) condition was also observed
in 3 out of 3 scaffolds retrieved in the rat study (Data
not shown). Thus we are confident that addition of gly-
cerophosphate for a week will not prevent endochondral
ossification as we observed in the switch 1 (full osteo-
genic medium switch). These findings would suggest
that pre-mineralisation alone will not prevent the pro-
cess of endochondral ossification occurring in-vivo. It is
likely another factor in the osteogenic medium that pre-
vents bone formation in-vivo, possibly the presence of
serum. The lack of retrieved samples in the human
MSC study can not be ignored however as it is possible
that these samples could not be retrieved because they
were resorbed by the host. Pre-mineralisation might
offer the advantage of stiffer scaffolds upon implantation
which would greatly improve the options in load bearing
situations and ideally reduce the time required for inter-
nal/external fixation.
The role of host and donor in endochondral ossification
Determining the origin of host and donor cells in this
type of experiment is a difficult task. Here we used trans-
genic rats expressing hPLAP into which we implanted
scaffolds containing wild type cells of the same inbred
strain. This approach has two goals. Firstly, to determine
the origin of the bone forming cells in the process of
endochondral ossification and secondly to confirm that
the results observed in immunocompromised mice could
be reproduced in immunocompetent animals. The utility
of this approach for the identification of donor/host cells
in a variety of tissues has been demonstrated previously
[13,14]. In accordance with the experiments using
human MSCs in immunocompromised mice, bone for-
mation occurred only under chondrogenic and b-glycero-
phosphate conditions in rats. Analysis of hPLAP
expression in the various tissues clearly demonstrated the
presence of host and donor-derived cells. Embedded in
the bone matrix, positively and negatively staining cells
were observed, suggestive of the presence of cells of both
host and donor origin, indicating that at least at earlier
time points the donor cells are actively involved in the
formation of bone. In order to clearly identify the roles of
both host and donor cells, a timecourse analysis coupled
with the reverse scenario (Transgenic cells into wild type
animals) should be performed. Eight weeks after implan-
tation all osteoblasts and lining cells were of host origin,
suggesting that the bone formed from that time point on
will be host derived.
Conclusions
The work presented in this article suggests that the
induction of chondrogenesis in vitro vs osteogenesis
offers an improved approach to bone repair and regen-
eration in vivo. As discussed in a previous article [6], we
believe this is in part due to the paracrine effects of
these cells with different release profiles of important
factors such as VEGF, MMPs and other growth factors
at critical stages in the process. It is clear from this
work that chondrogenic priming of cells, particularly of
adult human MSCs offers an extremely promising route
to bone formation and repair that will undoubtedly be
pursued in the coming years as an alternative to the
standard intramembranous ossification approach of tis-
sue engineering bone.
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